Bestat Group Welcomes Trifecta MedTek Co., Ltd.
On March 12, 2026, Bestat Group held an unveiling ceremony to mark the official integration of Trifecta MedTek Co., Ltd. into the group, representing an important milestone in the expansion of a comprehensive biotechnology service platform. The event welcomed numerous leaders and partners from the biotech and pharmaceutical industries, who gathered to witness this significant occasion.
During the ceremony, Samuel Su, CEO of Bestat Pharmaservices Corp., delivered remarks highlighting the strategic importance of the integration. With Trifecta now part of Bestat Group, the organization is able to offer a complete one-stop service platform spanning from preclinical research to human clinical trials, providing biotech and pharmaceutical companies with a more integrated and efficient development pathway.
Samuel also shared Bestat's long-term vision of enabling a Taiwan-based CRO to expand into the U.S. market, a goal that Bestat has been actively pursuing. He further expressed the aspiration to develop Bestat into a boutique CRO, emphasizing agility, specialization, and high-quality service as key differentiators in the global clinical research landscape.
In addition, Samuel introduced the idea of building a “Bio Team Taiwan,” encouraging stronger collaboration across Taiwan’s biotech ecosystem to collectively enhance the industry's international competitiveness.
Following the remarks, Samuel Su joined distinguished guests in unveiling the new nameplate, symbolizing Trifecta's official entry into the Bestat Group.
The ceremony concluded with a reception where guests exchanged insights and explored future collaboration opportunities, reflecting the industry's shared commitment to advancing biomedical innovation.
This integration also aligns with the United Nations Sustainable Development Goals, particularly SDG 3: Good Health and Well-being, by supporting the development of new medical innovations, and SDG 17: Partnerships for the Goals, through strengthened collaboration across the biotechnology sector.
Looking ahead, Bestat Group will continue to integrate resources, deepen partnerships, and work with industry stakeholders to strengthen Taiwan’s global competitiveness in the biopharmaceutical field.
News links:
1. https://www.ftvnews.com.tw/news/detail/2026313W0136
2. https://news.m.pchome.com.tw/living/mypeople/20260313/index-77337202225582219009.html
On March 12, 2026, Bestat Group held an unveiling ceremony to mark the official integration of Trifecta MedTek Co., Ltd. into the group, representing an important milestone in the expansion of a comprehensive biotechnology service platform. The event welcomed numerous leaders and partners from the biotech and pharmaceutical industries, who gathered to witness this significant occasion.
During the ceremony, Samuel Su, CEO of Bestat Pharmaservices Corp., delivered remarks highlighting the strategic importance of the integration. With Trifecta now part of Bestat Group, the organization is able to offer a complete one-stop service platform spanning from preclinical research to human clinical trials, providing biotech and pharmaceutical companies with a more integrated and efficient development pathway.
Samuel also shared Bestat's long-term vision of enabling a Taiwan-based CRO to expand into the U.S. market, a goal that Bestat has been actively pursuing. He further expressed the aspiration to develop Bestat into a boutique CRO, emphasizing agility, specialization, and high-quality service as key differentiators in the global clinical research landscape.
In addition, Samuel introduced the idea of building a “Bio Team Taiwan,” encouraging stronger collaboration across Taiwan’s biotech ecosystem to collectively enhance the industry's international competitiveness.
Following the remarks, Samuel Su joined distinguished guests in unveiling the new nameplate, symbolizing Trifecta's official entry into the Bestat Group.
The ceremony concluded with a reception where guests exchanged insights and explored future collaboration opportunities, reflecting the industry's shared commitment to advancing biomedical innovation.
This integration also aligns with the United Nations Sustainable Development Goals, particularly SDG 3: Good Health and Well-being, by supporting the development of new medical innovations, and SDG 17: Partnerships for the Goals, through strengthened collaboration across the biotechnology sector.
Looking ahead, Bestat Group will continue to integrate resources, deepen partnerships, and work with industry stakeholders to strengthen Taiwan’s global competitiveness in the biopharmaceutical field.
News links:
1. https://www.ftvnews.com.tw/news/detail/2026313W0136
2. https://news.m.pchome.com.tw/living/mypeople/20260313/index-77337202225582219009.html